Navigation Links
Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis

sing patients to lung infections, which continually damage their lungs. Pulmonary infection with Gram-negative bacteria, particularly pulmonary P. aeruginosa, represents the single greatest cause of morbidity and mortality among CF patients. Currently there is no known cure for CF, and the goal of CF therapy is to control symptoms and prevent further lung damage.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia. For more information on Gilead Sciences, please visit the company's website at www.gilead.com or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including statements related to Gilead's ability to obtain data from AIR-CF1 and submit an NDA for aztreonam lysine for inhalation for the treatment of CF to the U.S. FDA as currently planned. For example, the safety and efficacy data from additional clinical studies may not warrant further development of this compound and initiating and completing clinical trials may take longer or cost more than expected. In addition, future discussions with the FDA may impact the amount of data needed and timelines for review, which may differ materially from Gilead's current projections. Further, the U.S. FDA may not approve aztreonam lysine for inhalation for the treatment of CF in the United States, and any marketing approval, if granted, may have significant limitations on its use. These risks, uncertainties and other factors could cause actual results to differ materially fr
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
5. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
6. Data from Preclinical Studies of Gilead Nucleotide Compound GS 9219 to be Presented at AACR
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:9/15/2014)... /PRNewswire-iReach/ -- Asthma is a chronic inflammatory lung ... most commonly starts in childhood. It is a ... airways, leading to airflow limitation and airway hyper-responsiveness ... endogenous and exogenous irritants. Exposure to irritants instigates ... the airways, tightening of the respiratory muscles, and ...
(Date:9/15/2014)... , Sept. 15, 2014 /PRNewswire-iReach/ -- MedicOne Medical Response, ... services, has been selected by Inc. Magazine as ... America. Photo - http://photos.prnewswire.com/prnh/20140914/145997 ... list identifies successful, privately-held companies with the largest ... Response, one of only two ambulance companies to ...
(Date:9/15/2014)... Nev. , Sept. 15, 2014 PDL BioPharma, ... that it has paid the September 12, 2014, regular quarterly ... owning shares of PDL as of September 5, 2014, the ... PDL BioPharma manages a portfolio of patents and ... antibody humanization patents and license agreements with various biotechnology ...
Breaking Medicine Technology:Asthma Market to Reach 161.02 million Cases in 10MM by 2023 2Asthma Market to Reach 161.02 million Cases in 10MM by 2023 3Asthma Market to Reach 161.02 million Cases in 10MM by 2023 4Asthma Market to Reach 161.02 million Cases in 10MM by 2023 5MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 2MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 3PDL BioPharma Completes Regular Quarterly Dividend Payment 2
... to Prevent,and Reverse Atherosclerotic Heart Disease, EMERYVILLE, Calif., ... drug discovery and development company, announced,today the first ... in animals through the pathway known as reverse ... by which excess,cholesterol can be removed from tissues ...
... 14, 2007 - Acceleron Pharma,Inc., a biopharmaceutical ... metabolic and cancer-related,diseases, today announced results of ... ability of the compound to increase,muscle mass ... murine models of,muscular dystrophy. ACE-031 inhibits negative ...
Cached Medicine Technology:KineMed Presents Data Measuring Changes in Reverse Cholesterol,Transport for the First Time 2KineMed Presents Data Measuring Changes in Reverse Cholesterol,Transport for the First Time 3Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies 2Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies 3
(Date:9/15/2014)... 2014 Crosley Law Firm is proud to ... have been named to the list of Super Lawyers in ... of personal injury law. , Before receiving the designation ... selection process. First, they must come highly recommended by a ... noteworthy achievement during the past year by obtaining certain honors, ...
(Date:9/15/2014)... September 16, 2014 “Advanced First Aid for ... author Frank O’ Connor leads readers from occupational first aid ... first aid without any difficulty. There are over 165 photographs ... skill sets. , This book is an ideal reference ... course manual. It is in essence three books in one. ...
(Date:9/15/2014)... the University of Copenhagen have gained new knowledge ... The findings have recently been published in the ... The defining symptoms of Parkinson,s disease are slow ... no cure for the condition, so it is ... to shed some light on this terrible disruption ...
(Date:9/15/2014)... 2014)The Global Health Innovative Technology Fund (GHIT Fund), ... Japanese know-how and investment to the global fight ... totaling US$15.3 million to speed the development of ... diseasesmalaria, dengue and Chagas disease. The announcement marks ... since November 2013totaling $33.5 millionaimed at diseases that ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 College of Osteopathic ... recently sat in the lobby of Western University of Health ... Gomez. He asked Gomez about his medications, his blood pressure ... “He’s helping me a lot. He’s a good man,” Gomez ... student doctor and patient are part of the Longitudinal Chronic ...
Breaking Medicine News(10 mins):Health News:Thomas A. Crosley and R. Andrew Rodriguez Named 2014 Super Lawyers 2Health News:Frank O'Connor's new book explains importance of occupational and advanced first aid 2Health News:Researchers debunk myth about Parkinson's disease 2Health News:Japanese Global Health Fund awards $33.5 million to develop vaccines, drugs for neglected diseases 2Health News:Japanese Global Health Fund awards $33.5 million to develop vaccines, drugs for neglected diseases 3Health News:Japanese Global Health Fund awards $33.5 million to develop vaccines, drugs for neglected diseases 4Health News:Japanese Global Health Fund awards $33.5 million to develop vaccines, drugs for neglected diseases 5Health News:COMP Takes the Long View of Health Care 2Health News:COMP Takes the Long View of Health Care 3Health News:COMP Takes the Long View of Health Care 4
... collaboration between researchers at the Salk Institute for Biological ... the tumor suppressor p53, long thought of as the ... cancer-causing mutations. It may also prevent established cancer cells ... serving as a "Guardian against Genome Reprogramming." The ...
... St. Louis and a woman in New Hampshire have received ... program of the Organ Procurement and Transplantation Network (OPTN) that ... candidates with living donors. Both recipients Ken Crowder of ... loved ones who were willing to donate a kidney but ...
... discrimination among Mexican and Mexican American students from Phoenix-area ... stress when trying to acculturate with mainstream U.S. culture, ... experienced acculturation stress related to discrimination, they were at ... The study is in the December issue of ...
... , MONDAY, Dec. 13 (HealthDay News) -- A federal judge ... unconstitutional, saying the federal government has no authority to require ... a cornerstone of the new legislation, signed into law in ... not unexpected, and both supporters and opponents of the legislation ...
... million men and women ages 50 to 64 stand ... that expand access to affordable health insurance, assure that ... insurers from denying coverage or charging higher premiums to ... limits in health insurance policies, according to a new ...
... the activity of genes direct changes to the DNA ... genes are switched on and off, called epigenetic means. Tumor-suppressor ... for the cancerous growth of cells. Researchers at the ... on a genome-wide scale in cases of ovarian cancer. ...
Cached Medicine News:Health News:The stemness of cancer cells 2Health News:The stemness of cancer cells 3Health News:2 people receive kidney transplants in pilot program using CMU software 2Health News:2 people receive kidney transplants in pilot program using CMU software 3Health News:Drug use and discrimination among Phoenix area Mexican heritage youth 2Health News:Drug use and discrimination among Phoenix area Mexican heritage youth 3Health News:Federal Judge Strikes Down Health Reform Law 2Health News:Federal Judge Strikes Down Health Reform Law 3Health News:18.3 million baby boomers could benefit from the Affordable Care Act 2Health News:18.3 million baby boomers could benefit from the Affordable Care Act 3Health News:18.3 million baby boomers could benefit from the Affordable Care Act 4Health News:Ovarian cancer advances when genes are silenced 2
Cloward cervical retractor. Size 18 mm....
Large, removable blades, length 242 mm, (9 1/2"). Function: tissue retracting....
Toothed Pituitary IVD Rongeurs, 8 length 200 mm....
Suitable for children and adults. New mechanical design of the skull pin holder and the clamp base ensures improved rigid skull fixation....
Medicine Products: